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Factor VII deficiency is characterized by epistaxis, bruis- 
ing, hemarthrosis, mennorrhagia, gastrointestinal bleed- 
ing, hematuria, and intracranial hemorrhage during in- 
fancy. Causes of acquired factor VII deficiency include 
liver disease, Vitamin K deficiency, and warfarin admin- 
istration. Congenital factor VII deficiency is an autoso- 
real recessive disorder, with the homozygotes having a 
severe deficiency and the hetereozygotes a moderate de- 
ficiency of factor VII. Orthopedic, gynecological, car- 
diothoracic, and abdominal surgical procedures have 
been successfully performed in patients with factor VII 
deficiency both with and without factor VII replace- 
ment. We present two patients with moderate and mod- 
erately severe factor VII deficiency who successfully 
underwent  intracranial procedures using plasma during 
the perioperative period for factor VII replacement. One 
patient successfully underwent stereotactic placement of 
mesial temporal lobe depth electrodes and subdural strip 
electrodes followed by anterior temporal lobectomy for 
medically refractory seizures. The second patient suc- 
cessfully underwent craniotomy for an olfactory groove 
meningioma. No bleeding complications were encoun- 
tered with any of the three intracranial procedures per- 
formed. These cases represent the first reported cases of 
successful intracranial procedures in patients with factor 
VII deficiency, other than shunting procedures per- 
formed for intraventricular hemorrhage during infancy. 
KEY WORDS: Craniotomy; Factor VII deficiency; Neurosur- 
gery; Stereotactic 
Factor VII is a vitamin K-dependent protein synthesized 
by the liver. As part of the extrinsic clotting pathway, 
factor VII complexes with tissue factor, and in the 
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presence of calcium, activates factor IX [13]. Symptoms 
of factor VII deficiency include recurrent epistaxis, easy 
bruising, hemarthrosis, menorrhagia, gastrointestinal 
bleeding, hematuria, and intracranial hemorrhage 
[1,6,8,9,10,14]. Factor VII deficiency is either congeni- 
tal or acquired. Causes of acquired factor VII deficiency 
include liver disease, Vitamin K deficiency, and war- 
farin administration [8]. Congenital factor VII defi- 
ciency is inherited in an autosomal recessive pattern, 
with homozygotes having severe deficiency (0%-25%) 
and heterozygotes having a moderate deficiency (25%-  
75%) of factor VII [8]. In general, only those with 
severe deficiency are symptomatic, although there are 
marked variations in bleeding tendencies among pa- 
tients with similar degrees of deficiency [6,8,9,17]. 
Several case reports describe surgery in the presence 
of factor VII deficiency. Patients with severe factor VII 
deficiency have successfully undergone orthopedic, 
gynecological, cardiothoracic, and abdominal procedures 
[2,3,5,7,8,15,18]. During the perioperative period, fac- 
tor VII concentrate and/or plasma have been used to 
maintain hemostasis. However, successful surgery with- 
out factor VII replacement has also been reported 
[6,8,12,17]. 
Neurosurgical procedures require the most meticu- 
lous hemostatic control as even a small amount of 
bleeding, especially intracranially, is not tolerated with- 
out significant morbidity to the patient. Stereotactic 
procedures present an even greater challenge to the 
hemostatic mechanisms as little or no opportunity exists 
to control unexpected hemorrhage. We present two 
patients with factor VII deficiency who successfully 
underwent a total of three intracranial neurosurgical 
procedures using plasma for factor VII replacement. 
Case  1 
This patient is a 31-year-old, right-handed man with 
complex partial seizures refractory to medical therapy. 
Depth and subdural strip electrodes were indicated as 
noninvasive methods of localizing a seizure focus were 
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nondiagnostic. Bilateral mesial temporal depth elec- 
trodes and bilateral temporal neocortical subdural strip 
electrodes were recommended. However, during routine 
preoperative laboratory evaluation, the patient's pro- 
thrombin time (PT) was found to be 15.8 seconds, 1.3 
times control. Liver function and other coagulation 
studies, including platelet count, partial thromboplastin 
time (PTT), and bleeding time were within normal 
limits. This elevation of the prothrombin time corrected 
in vitro upon addition of 50% normal pooled plasma. 
The patient denied any prior bleeding problems, such 
as epistaxis, gingival bleeding, easy bruisability, or he- 
marthrosis. Prior surgical procedures including tonsil- 
lectomy as a child and tooth extractions as an adult were 
not complicated by hemorrhage. 
The patient then received parenteral Vitamin K sup- 
plementation for 1 week, but the PT remained elevated. 
Factor VII level was then measured at 46% of expected 
level, with 80% to 150% considered within normal 
limits. 
The patient first underwent placement of bilateral 
mesial temporal depth electrodes and bilateral temporal 
neocortical subdural strip electrodes. The patient's factor 
VII deficiency was managed with plasma, both fresh 
frozen and single donor. The patient received a total 
dose of 10 cc/kg with three units (one unit = approxi- 
mately 200 cc to 250 cc) transfused immediately prior 
to surgical incision and three units transfused intraoper- 
atively. No intraoperative bleeding difficulties were en- 
countered. 
Postoperatively, the patient received one unit of sin- 
gle donor or fresh frozen plasma every 8 hours until the 
fourth postoperative day. Meanwhile, seizure monitor- 
ing proceeded uneventfully. Daily PT was measured. 
However, on postoperative day 8, the PT rose above 15, 
and he then received one unit of plasma every 12 hours 
until the subdural strip and temporal lobe depth elec- 
trodes were removed at the bedside uneventfully. 
At a later date, the patient was readmitted to the 
hospital for a left anterior temporal lobectomy, which 
was done with the patient awake. Upon arrival to the 
operating room, he was immediately given three units 
of plasma, followed by another three transfused 
throughout the duration of the case. No intraoperative 
bleeding difficulties were encountered. Postoperatively, 
he was given one unit of plasma every 12 hours until 
postoperative day 3. He was discharged on the fourth 
postoperative day. He has remained seizure-free for 1 
year, and no infectious complications of transfusion have 
developed. 
Case 2 
A 66-year-old woman presented with a 1-year hisiory of 
personality changes, 3-month history of urinary inconti- 
nence, and a generalized tonic-clonic seizure. Computed 
tomography (CT) and magnetic resonance imaging 
(MRI) scans revealed a probable olfactory groove menin- 
gioma. 
Routine preoperative workup revealed an elevated PT 
of 14.9 (ratio of 1.2). Bleeding time, platelet count, 
PTT, fibrinogen, and fibrin split products were within 
normal limits. Mixing studies revealed the abnormal PT 
corrected in vitro upon addition of 50% normal pooled 
plasma. Factor VII level was 27% (normal = 80%-  
150%). 
The patient denied any prior bleeding problems. She 
had previously undergone two cesarean sections, an 
appendectomy, and a hysterectomy without any com- 
plications. 
Preoperatively the patient was given 10 cc/kg of 
plasma (four units). She underwent bifrontal craniotomy 
for removal of an olfactory groove meningioma, with 
fascia lata and pericranial grafts. No unexpected bleed- 
ing was encountered. Three units of plasma and one 
unit of packed red blood cells were given intraopera- 
tively. Postoperatively, her neurologic status remained 
unchanged. 
She was transfused with one unit of plasma every 12 
hours until the fourth postoperative day. An additional 
three units of packed red blood cells were also given 
during the immediate 48 hours postoperative. No 
bleeding complications were encountered, and the pa- 
tient made a full recovery. No infectious complications 
of transfusion have developed. 
Discuss ion  
Management of factor VII deficiency in surgical candi- 
dates is controversial. Given the variable bleeding ten- 
dencies among patients with severe deficiency, it is not 
surprising that surgical procedures have been safely 
performed without replacement therapy [6,8,12,17]. 
This observation led Yorke and Mant to recommend 
that routine preoperative replacement therapy is not 
justified, and transfusions should be given only if bleed- 
ing problems arise [17]. However, for severe deficien- 
cies, most authors recommend replacement therapy at 
least during and immediately after surgery. Strauss sug- 
gested transfusion of 10 mL of plasma per kg immedi- 
ately before major surgical procedures and 4 mL/kg 
every 4 hours through the first postoperative day [15]. 
Zimmerman et al recommended transfusion of 10 to 15 
units of factor VII concentrate per kg of body weight 
every 6 hours through the first three postoperative days 
[19]. Marder and Shulman recommended sufficient 
plasma transfusions to produce a factor VII level of 10% 
to 20% at the time of surgery and for several days 
postoperatively [8]. Obviously, replacement therapy is 
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not without hazard, with at least one reported case of 
antibody evidence of seroconversion to the human im- 
munodeficiency virus as a result of replacement therapy 
for factor VII deficiency in a patient undergoing hip 
replacement [2]. 
The two cases presented in this article represent 
moderate (patient #1, factor VII = 46%) and moder- 
ately severe (patient #2, factor VII = 28%) examples of 
factor VII deficiency. In the absence of hepatobiliary 
disease, warfarin treatment, and lack of response to 
Vitamin K therapy in patient #1, it is probable that 
both of these patients are heterozygous for congenital 
factory VII deficiency. Therefore, it is also likely that 
most surgical procedures could have been performed 
successfully without replacement therapy. 
However, intracranial procedures demand meticulous 
hemostasis. Minimal amounts of unexpected hemor- 
rhage can result in significant morbidity and mortality. 
Both cases illustrate situations where hemostasis is chal- 
lenged beyond other intracranial procedures. The first 
patient successfully underwent stereotactic placement of 
mesial temporal lobe depth electrodes and subdural 
temporal strip electrodes. This procedure is performed 
through four small (approximately 10 mm) trephines, 
two each placed symmetrically in the temporal and 
occipital regions. Intracranial hemostasis can be surgi- 
cally maintained only at the dural and pial surfaces 
immediately beneath the trephine. The body's natural 
hemostatic mechanisms provide the only other barrier to 
uncontrolled hemorrhage within the substance of the 
brain or on the surface of the temporal lobe inaccessible 
through the small opening in the skull. The second 
patient underwent uneventful removal of an olfactory 
groove meningioma, a tumor that frequently is vascular 
and occasionally requires transfusion of blood in patients 
without a coagulopathy. 
Given the grave consequences of unexpected intra- 
cranial hemorrhage, we elected to transfuse our patients 
with plasma for replacement of their factor VII defi- 
ciency. Immediately preoperatively 10 cc of plasma per 
kg of body weight was given, followed by one unit of 
plasma every 8 to 12 hours postoperatively through at 
least the third postoperative day and as long as 12 days 
postoperatively in patient #1 while intracranial record- 
ing electrodes were in place. 
These two cases illustrate another controversial issue. 
As neither patient had a history of a bleeding disorder 
and were both otherwise healthy, one may question the 
necessity of obtaining a preoperative coagulation profile 
in these patients. After reviewing the medical records of 
3782 healthy patients scheduled to undergo an elective 
surgical procedure, Narr et al concluded that routine 
preoperative screening tests were not indicated for 
healthy subjects under age 40 [11]. Suchman and 
Griner suggest that obtaining PT and PTT preopera- 
tively is not indicated in the absence of either historical 
or physical evidence of a coagulopathy [16]. However, 
preoperative coagulation screening may be justified in 
the present patients for several reasons. In case #1, the 
patient had been on chronic phenytoin therapy, which 
has known hepatotoxic properties [4], In case #2, the 
patient was 66 years old. According to Narr, a patient 
older than 60 years is an indication for a more extensive 
preoperative laboratory workup [11]. One may also 
argue that any intracranial procedure is an indication for 
routine preoperative coagulation profile given the grave 
consequences of uncontrolled hemorrhage. 
These two cases represent, to the best of our knowl- 
edge, the only published cases of intracranial procedures 
performed on patients with factor VII deficiency other 
than shunting procedures after intracranial hemorrhage 
in childhood [1,14]. Our experience indicates that 
patients with moderate to moderately severe factor VII 
deficiency can safely undergo intracranial procedures 
using plasma transfusions during the perioperative 
period. 
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